Genome-wide Analysis of Noncoding Regulatory Mutations in Cancer

Overview

Journal Nat Genet

Specialty Genetics

Date 2014 Sep 29

PMID 25261935

Citations 297

Authors

Nils Weinhold

Anders Jacobsen

Nikolaus Schultz

Chris Sander

William Lee

Affiliations

Soon will be listed here.

Abstract

Cancer primarily develops because of somatic alterations in the genome. Advances in sequencing have enabled large-scale sequencing studies across many tumor types, emphasizing the discovery of alterations in protein-coding genes. However, the protein-coding exome comprises less than 2% of the human genome. Here we analyze the complete genome sequences of 863 human tumors from The Cancer Genome Atlas and other sources to systematically identify noncoding regions that are recurrently mutated in cancer. We use new frequency- and sequence-based approaches to comprehensively scan the genome for noncoding mutations with potential regulatory impact. These methods identify recurrent mutations in regulatory elements upstream of PLEKHS1, WDR74 and SDHD, as well as previously identified mutations in the TERT promoter. SDHD promoter mutations are frequent in melanoma and are associated with reduced gene expression and poor prognosis. The non-protein-coding cancer genome remains widely unexplored, and our findings represent a step toward targeting the entire genome for clinical purposes.

Citing Articles

Tumor protein 53 gene polymorphism, demographic attributes and associated risk factors among liver cancer patients in Calabar, Nigeria.

Ekpenyong B, Ubi G, Kooffreh M, Umoyen A, James C, Ettah I BMC Cancer. 2025; 25(1):430.

PMID: 40065269 PMC: 11892161. DOI: 10.1186/s12885-025-13803-y.

Noncoding variation near UBE2E2 orchestrates cardiometabolic pathophenotypes through polygenic effectors.

Zhang Y, David N, Pesaresi T, Andrews R, Kumar G, Chen H JCI Insight. 2024; 10(2).

PMID: 39656538 PMC: 11790016. DOI: 10.1172/jci.insight.184140.

Melanoma-specific mutation hotspots in distal, non-coding, promoter-interacting regions implicate novel candidate driver genes.

Pudjihartono M, Pudjihartono N, OSullivan J, Schierding W Br J Cancer. 2024; 131(10):1644-1655.

PMID: 39367275 PMC: 11555344. DOI: 10.1038/s41416-024-02870-w.

Determinants of gastric cancer immune escape identified from non-coding immune-landscape quantitative trait loci.

Miliotis C, Ma Y, Katopodi X, Karagkouni D, Kanata E, Mattioli K Nat Commun. 2024; 15(1):4319.

PMID: 38773080 PMC: 11109163. DOI: 10.1038/s41467-024-48436-5.

The Application of Long-Read Sequencing to Cancer.

Ermini L, Driguez P Cancers (Basel). 2024; 16(7).

PMID: 38610953 PMC: 11011098. DOI: 10.3390/cancers16071275.

References

Andersson R, Gebhard C, Miguel-Escalada I, Hoof I, Bornholdt J, Boyd M . An atlas of active enhancers across human cell types and tissues. Nature. 2014; 507(7493):455-461. PMC: 5215096. DOI: 10.1038/nature12787. View

Lawrence M, Stojanov P, Mermel C, Robinson J, Garraway L, Golub T . Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014; 505(7484):495-501. PMC: 4048962. DOI: 10.1038/nature12912. View

Chen C, Rappailles A, Duquenne L, Huvet M, Guilbaud G, Farinelli L . Impact of replication timing on non-CpG and CpG substitution rates in mammalian genomes. Genome Res. 2010; 20(4):447-57. PMC: 2847748. DOI: 10.1101/gr.098947.109. View

Church D, Briggs S, Palles C, Domingo E, Kearsey S, Grimes J . DNA polymerase ε and δ exonuclease domain mutations in endometrial cancer. Hum Mol Genet. 2013; 22(14):2820-8. PMC: 3690967. DOI: 10.1093/hmg/ddt131. View

Stirnimann C, Petsalaki E, Russell R, Muller C . WD40 proteins propel cellular networks. Trends Biochem Sci. 2010; 35(10):565-74. DOI: 10.1016/j.tibs.2010.04.003. View

Artez A, Bernabe R, Eerola I, Hemsley F, Jennings J, Kerr D . International network of cancer genome projects. Nature. 2010; 464(7291):993-8. PMC: 2902243. DOI: 10.1038/nature08987. View

Schneider C, Pasqualucci L, Dalla-Favera R . Molecular pathogenesis of diffuse large B-cell lymphoma. Semin Diagn Pathol. 2011; 28(2):167-77. PMC: 3562715. DOI: 10.1053/j.semdp.2011.04.001. View

Chapman M, Lawrence M, Keats J, Cibulskis K, Sougnez C, Schinzel A . Initial genome sequencing and analysis of multiple myeloma. Nature. 2011; 471(7339):467-72. PMC: 3560292. DOI: 10.1038/nature09837. View

Weinstein J, Collisson E, Mills G, Mills Shaw K, Ozenberger B, Ellrott K . The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet. 2013; 45(10):1113-20. PMC: 3919969. DOI: 10.1038/ng.2764. View

10.

Virgilio L, Narducci M, Isobe M, Billips L, Cooper M, Croce C . Identification of the TCL1 gene involved in T-cell malignancies. Proc Natl Acad Sci U S A. 1994; 91(26):12530-4. PMC: 45472. DOI: 10.1073/pnas.91.26.12530. View

11.

Killela P, Reitman Z, Jiao Y, Bettegowda C, Agrawal N, Diaz Jr L . TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013; 110(15):6021-6. PMC: 3625331. DOI: 10.1073/pnas.1303607110. View

12.

Huang F, Hodis E, Xu M, Kryukov G, Chin L, Garraway L . Highly recurrent TERT promoter mutations in human melanoma. Science. 2013; 339(6122):957-9. PMC: 4423787. DOI: 10.1126/science.1229259. View

13.

Lawrence M, Stojanov P, Polak P, Kryukov G, Cibulskis K, Sivachenko A . Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218. PMC: 3919509. DOI: 10.1038/nature12213. View

14.

Baysal B, Ferrell R, Willett-Brozick J, Lawrence E, Myssiorek D, Bosch A . Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science. 2000; 287(5454):848-51. DOI: 10.1126/science.287.5454.848. View

15.

Futreal P, Coin L, Marshall M, Down T, Hubbard T, Wooster R . A census of human cancer genes. Nat Rev Cancer. 2004; 4(3):177-83. PMC: 2665285. DOI: 10.1038/nrc1299. View

16.

Lee W, Jiang Z, Liu J, Haverty P, Guan Y, Stinson J . The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature. 2010; 465(7297):473-7. DOI: 10.1038/nature09004. View

17.

Thukral S, Eisen A, Young E . Two monomers of yeast transcription factor ADR1 bind a palindromic sequence symmetrically to activate ADH2 expression. Mol Cell Biol. 1991; 11(3):1566-77. PMC: 369446. DOI: 10.1128/mcb.11.3.1566-1577.1991. View

18.

Horn S, Figl A, Rachakonda P, Fischer C, Sucker A, Gast A . TERT promoter mutations in familial and sporadic melanoma. Science. 2013; 339(6122):959-61. DOI: 10.1126/science.1230062. View

19.

Niemann S, Muller U . Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet. 2000; 26(3):268-70. DOI: 10.1038/81551. View

20.

Cibulskis K, Lawrence M, Carter S, Sivachenko A, Jaffe D, Sougnez C . Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013; 31(3):213-9. PMC: 3833702. DOI: 10.1038/nbt.2514. View